SAMSON MARVIN 4
4 · ANTARES PHARMA, INC. · Filed Jan 6, 2020
Insider Transaction Report
Form 4
SAMSON MARVIN
Director
Transactions
- Exercise/Conversion
Common Stock
2020-01-02$2.66/sh+549$1,460→ 52,300 total - Sale
Common Stock
2020-01-02$4.60/sh−549$2,525→ 51,751 total - Exercise/Conversion
Stock Option (right to buy)
2020-01-02−99,395→ 0 totalExercise: $2.18From: 2016-05-28Exp: 2025-05-27→ Common Stock (99,395 underlying) - Exercise/Conversion
Stock Option (right to buy)
2020-01-02−549→ 0 totalExercise: $2.66From: 2018-06-07Exp: 2027-06-06→ Common Stock (549 underlying) - Exercise/Conversion
Common Stock
2020-01-02$2.18/sh+50,000$109,000→ 101,751 total - Sale
Common Stock
2020-01-02$4.59/sh−50,000$229,500→ 51,751 total - Exercise/Conversion
Common Stock
2020-01-02$2.18/sh+49,395$107,681→ 101,146 total - Sale
Common Stock
2020-01-02$4.60/sh−49,395$227,217→ 51,751 total
Footnotes (3)
- [F1]The stock option exercises and sales of common stock reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established in connection with estate planning.
- [F2]The options vested and became excercisable in four quarterly installments over the one-year period following the grant date of May 28, 2015.
- [F3]The options vested and became exercisable in four quarterly installments over the one-year period following the grant date of June 7, 2017.